6 FEC 100 Vs 4 FEC 100 Followed by 4 Taxol in N+ Breast Cancer
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government.
Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT00189644
Recruitment Status : Unknown
Verified September 2005 by Association Européenne de Recherche en Oncologie. Recruitment status was: Active, not recruiting
The main objective of this randomized trial is to compare 6 FEC100 to 4 FEC100 + 4 Taxol in patients with resected node positive breast cancer. Main endpoint is disease free survival. Secondary endpoints are overall survival, time to local recurrence, time to distant metastases, and tolerance. A total of 840 patients have been included in the trial.
Condition or disease
Procedure: 6 FEC 100Procedure: 4 FEC 100 followed by 4 Taxol
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.